参考来源: Tewari KS, Colombo N, Monk BJ, et al. Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer subgroup analyses from the KEYNOTE-826 randomized clinical trial. JAMA Oncol. Published online December 14, 2023. doi:10.1...
Introduction The prognosis of patients with recurrent and/or metastatic cervical cancer remains poor, with a 5-year survival rate of 17%. Most of cervical cancers are associated with the human papillomavirus (HPV) infection that leads to viral antigens production, supporting the development of ...
4. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856-1867. doi:10.1056/NEJMoa2112435
Tewari KS, Colombo N, Monk BJ, et al. Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer subgroup analyses from the KEYNOTE-826 randomized clinical trial. JAMA Oncol. Published online December 14, 2023. doi:10.1001/jamaonc...
标题:Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study. 期刊:Cancer Im...
KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined...
Metastatic or unresectable, recurrent HNSCC Metastatic gastric cancer; if not detected in an archival gastric cancer specimen, consider obtaining a tumor biopsy for PD-L1 testing Locally advanced or metastatic esophageal cancer Recurrent or metastatic cervical cancer Combination therapy Locally recurrent un...
KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by...
Expert discusses the long wait for an effective therapeutic option for persistent, recurrent, or metastatic cervical cancer and the potential widespread benefits of antibody drug conjugates like pembrolizumab. Bradley J. Monk, MD, Division of Gynecological Oncology, H...
cancer of the cervix or uterus; advanced stomach or esophageal cancer; locally advanced unresectable or metastatic biliary tract cancer (BTC) or a type of cancer that laboratory testing proves to have certain specific DNA mutations. Pembrolizumab is often given when the cancer has spread to other ...